FDA Approves Golimumab for Patients with pJIA & Psoriatic Arthritis

The FDA has approved golimumab for the treatment of pediatric patients with active polyarticular juvenile idiopathic arthritis or active psoriatic arthritis...

Source: The Rheumatologist - October 21, 2020 Category: Rheumatology Authors: Michele B. Kaufman, PharmD, BCGP Tags: Biologics & Biosimilars Drug Updates FDA approval Golimumab Pediatric polyarticular juvenile idiopathic arthritis polyarticular juvenile idiopathic arthritis (JIA) psoriatic arthritis U.S. Food and Drug Administration (FDA) Source Type: research